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ABSTRACT
A move is under way towards personalised
cancer treatment, where tumour biology of an
individual patient is examined to give unique
predictive and prognostic information. This is
extremely important in the setting of older
women, who have treatment-specific goals
which may differ from their younger counter-
parts, and may include conservation of quality
of life rather than curative intent of treatment.
One method employed to assist with this is the
use of tumour-based prognostic and predictive
tools. This article explores six of the most
common tumour-based tools currently available
on the market: MammaPrint, Oncotype DX,
Mammostrat, Prosigna, EndoPredict, IHC4. The
article discusses the creation and validation of
these tools, their use and validation in older
women, and future directions in the field. With
the exception of Oncotype Dx, which has also
been licensed for prediction of response from
adjuvant chemotherapy, these tools have been
licensed for use as prognostic tools only, mainly
in the setting of adjuvant therapy following
surgery. The evidence base for use in older
women is strongest for Mammostrat and
PAM50, although overall the evidence is much
weaker than that in younger women. Where
older women have been included in validation
studies, this is often in small numbers, or the
exact proportion of older women is unknown.
In practice, all six of the tools are recommended
to be utilised on surgical excision specimens, as
well as in core needle biopsy (CNB) specimens
in all of the tools except Mammostrat. This is
extremely important in the setting of older
women, of whom a large proportion do not
undergo surgery. The suggested nature of the
sample is formalin-fixed paraffin-embedded in
all the tools except MammaPrint, which can
also be performed on fresh-frozen samples.
Future development of prognostic tools in older
women with breast cancer should focus on
treatment dilemmas specific to this population.
This includes the decision of primary treatment
between surgery or endocrine therapy and
decisions regarding adjuvant therapy, in par-
ticular, chemotherapy.
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Key Summary Points
There are many tumour-based prognostic
and predictive tools on the market;
however, these tools have been primarily
derived from and tested in younger
women.
Assessment of tumour biology is
extremely important in primary breast
cancer in older women, who have specific
treatment goals and concerns.
The evidence base for use of six of the
most common tumour-based tools
(MammaPrint, Oncotype Dx,
Mammostrat, Prosigna, EndoPredict and
IH4) is much weaker in the older
compared to younger population.
The majority of existing tools focus on
prognosis after adjuvant therapy
following surgery and do not consider the
unique needs of the older population.
Many of these tools have been utilised on
core needle biopsy specimens, which is
important when examining biology in
older women, as a large proportion do not
undergo surgical treatment.
INTRODUCTION
Current Challenges in the Older
Population
Breast cancer is more common in older women;
nearly half of all diagnoses are made in patients
over 65 years of age [1], and this will continue
to increase with the ageing population [2].
Despite this, older women are often under-rep-
resented in clinical trials.
There is a growing body of evidence to sug-
gest that the biology of breast cancer differs in
older compared to younger women [3–5]. A
better understanding of these differences has
the potential to alter the management of breast
cancer in older women at every stage of the
pathway, including consideration of neoadju-
vant treatment, primary treatment, adjuvant
treatment and treatment of recurrent disease.
One example is the use of primary endocrine
therapy (PET) as an alternative option to surgery
in patients with oestrogen receptor (ER)-posi-
tive tumours. Although PET is only recom-
mended for patients who have a limited life
expectancy of 2–3 years [6], around 40% of
older women have previously been found to
receive this treatment [7, 8]. Therefore, treat-
ment decision-making in clinical practice is not
as straightforward, as there are numerous other
reasons that an older patient might not want
surgery, related to frailty, competing causes of
death and maintenance of quality of life.
In common with other regulatory bodies, the
National Institute for Health and Care Excel-
lence (NICE) provides no age-specific guidelines
on the management of breast cancer in the UK.
A move is under way towards personalised
cancer treatment, where tumour biology of an
individual patient is examined to give unique
predictive and prognostic information. This is
even more important in the setting of older
women, to direct the healthcare team and the
patient to decide on the most appropriate
treatment plan specific to them.
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
The Role of Predictive and Prognostic
Tools
Prognostic tests inform us about a possible
cancer outcome (recurrence of the disease, dis-
ease regression, death), independent of treat-
ment, over a specified time-period [9].
Predictive tests provide information on
response to a specific treatment [10].
Some tools to help inform the prognosis and
response to therapy do exist. The Nottingham
Prognostic Index (NPI) [11] was the first tool of
its kind to assess a combination of factors. This
includes histological grade which reflects
tumour biology, together with size of tumour
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and nodal status (time-dependent factors), to
inform prognosis following surgery. More
comprehensive assessment tools have been
developed in tools such as Adjuvant! Online
[12], which uses more clinicopathological fea-
tures; however, recruitment of older women in
their conception is lacking. The aims of these
tools are not focused on the treatment dilem-
mas of the older population. Furthermore, these
tools do not require unique tumour material to
be assessed from an individual patient, so are
not truly personalised to that patient.
To provide information specific to an indi-
vidual patient, unique material from the
patient’s tumour is required, rather than using
standard clinicopathological variables such as
tumour grade and size. Assessment of patient
tissue can be protein or genomic based.
Patients who have been identified as ‘low risk’
of recurrence by tools of this kind have been
shown to have a very low risk of metastatic dis-
ease after extensive follow-up. A study by Stem-
mer et al. [13] examined 1365 women from the
Clalit Health Services Registry with node-nega-
tive, ER-positive, human epidermal growth fac-
tor receptor 2 (HER2)-negative breast cancer who
underwent Oncotype DX testing between the
years 2006 and 2009. The median age of the
group was 60 years (standard deviation 52–-
66 years). The study was relatively well repre-
sented inolderwomen: 473women (34.7%)were
aged 60–69 years, 201 (14.7%) were 70–79 years
and 17% (1.3%) were over 80 years. The break-
down by Oncotype DX recurrence score (RS)
score was RS 0–10, 17.8%; RS 11–25, 62.5%; and
RS 26–100, 19.7%. The outcomes showed that
patientswith a lowandmedianRS, ofwhomonly
10% were treated with chemotherapy, had good
outcomes. The low-score group had a 10-year
distant recurrence of 2.6% and breast cancer-
specificmortality of 0.7%, and themedian group
was 6.1%and13.1%, respectively. These findings
support the evidence for Oncotype DX as a tool
for identifying low-risk patients where it is pos-
sible to treat with endocrine therapy alone.
In this paper, we will discuss six of the most
well-known tumour-based tools in chronologi-
cal order of their conception: MammaPrint,
Oncotype DX, Mammostrat, Prosigna (PAM50),
EndoPredict, IHC4. We will outline the clinical
use of each tool, development and validation,
with specific interest to validation in older
women, as well as possible future directions for
the tool. Following this, we will conclude whe-
ther there is enough evidence for use of these
tools routinely in the setting of primary breast
cancer in older women.
The development of each of the six tools, as
well as their validation studies, were all per-
formed on surgical excision samples.
TUMOUR-BASED TOOLS
Table 1 gives a summary of the six tumour-
based tools discussed in this article.
MammaPrint
Clinical Utility
The MammaPrint assay is a prognostic test
based on the assessment of a panel of 70 genes
[14]. It is designed for use in women with early
(stage I or II) breast cancer, B 5 cm size, with up
to three positive lymph nodes, irrespective of
hormone receptor (HR) status [15].
The gene expression profile of the patient is
comparedwith a template profile of a known risk
and subsequently categorises the patient into
either high or low risk of recurrence. A high-risk
result means that a patient has an 11.7% chance
that her cancer will recur in 5 years, and a low-
risk result has a 1.3% chance [16]. This result
should help to inform the healthcare team of the
likely benefit from adjuvant therapy.
In Europe, the MammaPrint assay is cur-
rently only available at the Agendia laboratory
in the Netherlands and takes 10 days to return a
result. In the USA, it is processed centrally in
California. Therefore, MammaPrint is not cur-
rently recommended by NICE for guiding
adjuvant therapy; the body has deemed it not
cost-effective at the present time [15].
Development of the Tool
The test was developed in 2002 at the Nether-
lands Cancer Institute using samples from sur-
gical specimens of 78 patients with primary,
node-negative breast cancer, tumours of
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size\ 5 cm, irrespective of HR status and in
patients aged\55 years [17]. A panel of around
25,000 genes was measured by DNA microarray
analysis. Following a series of applied supervised
classification, the optimal number of marker
genes was reached (70). Classification of high or
low risk of recurrence is based on measurement
of these 70 marker genes and whether the
patients in this cohort developed distant
metastases.
Validation of the Tool
MammaPrint was initially validated by the same
team surgical samples from the fresh-frozen
tissue bank of the Netherlands Cancer Institute
[18]. The validation cohort consisted of 295
women, aged\53 years, with stage I or II breast
cancer and tumours B 5 cm. The cohort inclu-
ded 61 patients who were also included in the
development sample [19]. The study measured
the 70-gene panel in these patients and evalu-
ated the prognostic power of the tool at pre-
dicting distant metastasis. Regression analysis
showed that the assay was a strong independent
factor in predicting distant metastasis.
MammaPrint is only licensed for use in the
adjuvant setting, although one study [20]
looked at its ability to analyse chemosensitivity
in the neoadjuvant setting. Tumour biopsies
were taken prior to treatment from 171 patients
treated at the Netherlands Cancer Institute. Of
the samples, 144 (86%) were deemed at high
risk of recurrence based on the MammaPrint
score. The results showed that those shown to
have a poor prognosis by MammaPrint were
more likely to achieve a pathological complete
response (pCR), compared to those shown to
have a good prognosis. Within the group of
patients at high risk of recurrence, 29 (20%)
achieved pCR, compared to none of the patients
at low risk of recurrence. The study suggests that
MammaPrint could be utilised in core needle
biopsy (CNB) samples, to help predict those
patients who may benefit from neoadjuvant
therapy.
Mayordomo et al. [21] have also presented
the results of a study investigating the use of
MammaPrint in samples obtained from CNB. A
total of 52 patients who had stage II or III breast
cancer and planned to have neoadjuvant
chemotherapy were included in the study.
MammaPrint was successfully applied to 34
CNBs. Of these, three (9%) were assigned to the
low risk category for recurrence and 31 cases
were predicted to be high risk. The study con-
cluded that MammaPrint could be conducted in
the majority of CNB specimens. This study has a
small sample size and is not specific to older
women; however, along with the study by
Straver et al. [20], it provides promising results
which suggest that MammaPrint could poten-
tially be applied to CNB samples prior to deci-
sion of primary treatment.
MammaPrint is also the only tool which has
been tested in vacuum-assisted biopsy (VAB)
specimens. This common technique provides
more tissue than standard CNB, but less tissue
than SE. A study by Osaki et al. [22] studied 67
patients with early-stage breast cancer. For each
patient, five to 10 biopsies were taken, two of
which were used for the analysis. MammaPrint
was successfully performed on 50 of the samples
and defined 22 cases (44%) as low risk and 28
cases (56%) as high risk. Information about the
age of the patients was not provided.
Validation of the Tool in Older Women
Since the initial data from the Netherlands,
there have been further validation studies, but
studies including older women are still lacking.
The Microarray In Node-negative Disease
may Avoid ChemoTherapy (MINDACT) trial
includes patients up to 70 years of age [23]. The
MINDACT trial is the first randomised con-
trolled trial using a tumour-profiling test in
clinical practice; others have been retrospective
in nature.
The MINDACT multicentre trial recruited
6693 patients from 112 institutions across nine
European countries [23]. The median age of the
patients was 55 years (range 23–71). The study
compared the patient’s genomic risk (using
MammaPrint) with their clinical risk (using
Adjuvant! Online). Women with both high
genomic and high clinical risk received
chemotherapy. The primary goal was to assess
the prognosis of those with low genomic and
high clinical risk who did not receive
chemotherapy. A total of 1550 (23.2%) women
were in this category; 1000 of these patients
Oncol Ther
(64.5%) were aged 50–70 and 16 women (1%)
were aged[70 years. At 5-year median follow-
up, there was no significant difference the in
rate of survival between those who received
chemotherapy and those who did not; however,
the study was not sufficiently powered to test
this. The trial is ongoing. The results so far have
led the American Society of Clinical Oncologists
(ASCO) to include MammaPrint in their guide-
lines. They recommend the use of MammaPrint
for those with early breast cancer deemed at
high clinical risk of recurrence, to identify
patients with a good prognosis irrespective of
adjuvant chemotherapy [21, 24].
Summary
The ongoing MINDACT trial shows the potential
ofMammaPrint as a predictive tool of response to
chemotherapy as adjuvant therapy. The inclusion
of some older women is a positive start, however
not enough to enable results of this study to be
applicable to older women in general. Further
studies are needed to assess the usefulness of
MammaPrint in women C 65 years of age.
Oncotype DX
Clinical Utility
Oncotype DX is a 21-gene assay that assesses the
expression of five reference genes (beta-actin
[ACTB], GAPDH, GUS, RPLPO, and TFRC) and
16 cancer-related genes (Ki67, STK15, survivin
or BIRC5, CCNB1 or cyclin B1, MYBL2, GRB7,
HER2, ER, progesterone receptor [PgR], BCL2,
SCUBE2, MMP11 or stromelysin 3, CTSL2 or
cathepsin L2, GSTM1, CD68, and BAG1). The
test is available for women with stage I or II, ER-
positive, HER2-negative breast cancer with up
to three positive lymph nodes [25]. The assay
uses an algorithm to derive a recurrence score
(RS), which is a continuous score from 0 to 100,
with a higher number indicating a greater
chance of recurrence at 10 years [26]. The tool
has also been approved for use in predicting the
likely benefit of adjuvant chemotherapy and
remains the only assay to date proven to be
useful in this context [26].
Currently, Oncotype DX is only available
from a central laboratory in California, USA,
and samples obtained from surgery must be sent
to this laboratory for testing.
In the UK, NICE has approved Oncotype DX
for use in patients with ER-positive, HER2-neg-
ative, lymph node-negative breast cancer,
where the patient had an intermediate risk of
disease with the PREDICT or Nottingham
Prognostic Index tools [26].
Development of the Tool
The assay was developed in 2004 by Genomic
Health (Redwood, CA) and has been available in
the UK since 2007 [25]. Initially, 250 potential
genes were analysed in three independent clin-
ical studies involving a total of 447 patients
with early invasive breast cancer and the rela-
tionship between gene expression and recur-
rence measured. Statistical analysis selected the
final 16 genes and five reference genes as the
minimum panel to obtain predictive informa-
tion regarding recurrence [27].
Validation of the Tool
The primary validation study was a retrospec-
tive analysis using the National Surgical Adju-
vant Breast and Bowel Project (NSABP) B-14 and
B-20 trial [27] data. The B-14 was a randomised
trial comparing outcomes for patients after
surgery to 5 years of tamoxifen or 5 years of
placebo. The B-20 trial was later created to
investigate adding chemotherapy to tamoxifen
in node-negative patients who had ER-positive
tumours [28].
Paik et al. [27] validated the prognostic util-
ity of Oncotype DX using the B-14 trial, which
comprised 668 patients. The levels of the genes
and subsequent recurrence score determined a
risk group for each patient: low, intermediate or
high. No age range is given in this validation
study, but 301 (45%) were aged[ 60 years. The
team showed that Oncotype DX score could
predict recurrence, independent of age and
tumour size.
A subsequent validation by the same team
was performed in the B-20 trial [29]. The specific
aim of this validation study was to understand
the ability of Oncotype DX to predict benefit
from chemotherapy. A total of 651 women were
assessed, 227 of whom were randomly assigned
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tamoxifen and 424 tamoxifen plus chemother-
apy. The study showed that patients who were
in the high-risk group as determined by Onco-
type DX had a significant benefit from
chemotherapy. Subgroup analysis by age was
not performed in this study; however, 196
(30%) of the participants were aged[60 years.
The tool’s performance has been explored in
the neoadjuvant setting. Three of four studies
with this aim have measured Oncotype DX in
pretreatment CNB specimens. All of the studies
have demonstrated that pCR was only found in
patients with a high RS ([ 25) [30–33].
Although not formally validated for this pur-
pose, Oncotype DX may be able to help predict
response to neoadjuvant therapy.
Most recently, in response to the COVID-19
pandemic, Oncotype DX has been extensively
tested in over 900,000CNB specimens. The study
concluded that Oncotype DX can be reliably
performed on CNB with consistent results to
those achieved in surgical samples [34].
Validation of the Tool in Older Women
Since initial validation, there has been an
abundance of studies incorporating Oncotype
DX. Of note is the Southwest Oncology Group
(SWOG) 8814 study [35], which tested Onco-
type DX in a cohort of 367 postmenopausal
women with ER-positive, node-positive breast
cancer. The age range of participants was 42–-
81 years, and 108 (29.4%) were aged C 65 years.
The results suggest that Oncotype DX predicted
a benefit of chemotherapy, even in patients
with node-positive disease. Unfortunately, sub-
group analysis by age was not performed.
The Trial Assigning Individualized Options
for Treatment (TAILORx) study was developed
to look at women with an intermediate-risk RS
(score 11–25) and whether they would benefit
from chemotherapy [36]. This is a prospective
trial involving 10,273 women with ER-positive,
HER2-negative, node-negative breast cancer.
The women were divided into a low-risk group
(score below 10, who were given adjuvant
endocrine therapy only), a high-risk group
(score above 26, who received chemoendocrine
therapy) and those with intermediate risk (score
of 11–25). The intermediate group in total
comprised 6711 who were randomised to
receive either chemoendocrine therapy or
endocrine therapy. The age range of partici-
pants was 23–75 years, but in the intermediate-
risk cohort only 291 (4.3%) were
aged[70 years. The 9-year rate of distant
recurrence in the intermediate group was 4%,
irrespective of chemotherapy use. The study
concluded that Oncotype DX might be partic-
ularly useful for predicting women who do not
need adjuvant chemotherapy [36].
Considering the results from TAILORx, ASCO
updated their guidelines forOncotypeDX in2019
[37]. They now recommendOncotype DX for use
in ER-positive, HER-2 negative, lymph node-neg-
ative breast cancer to guide adjuvant therapy.
Unlike NICE in the UK, the guidelines are age-
specific. ASCO recommends that those over
50 yearsof agewithanOncotypeDXRSof\26or
under 50 years of age with a score of\16 should
be offered endocrine therapy alone, on the basis
that there is no benefit to chemotherapy.Women
with an RS score[30 should be offered
chemoendocrine therapy. Finally, women in the
26–30 RS score category may be offered
chemoendocrine therapy; however, this recom-
mendation is not as strong [30–33].
Summary
To date, validation studies of Oncotype DX
have been restricted to younger women or have
included only a limited number of older
women. The RxPONDER (Rx for Positive Node,
Endocrine Responsive Breast Cancer) trial [38] is
an ongoing multicentre, phase III prospective
study. It aims to include 9400 women with
hormone receptor-positive, HER2-negative
breast cancer, with 1–3 positive nodes and
deemed at low risk of recurrence by Oncotype
DX. The study is randomising patients to the
use of adjuvant endocrine alone or endocrine
plus chemotherapy. The trial has no age limi-
tations and therefore may provide valuable data
on the use of Oncotype Dx in older women.
Mammostrat
Clinical Utility
The Mammostrat assay measures five biomark-
ers by immunohistochemistry: p53, HTF9C,
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CEACAM5, NDRG1, SLC7A5 [39] on surgical
specimens. The assay can be performed in
patients with early (stage I or II), ER-positive,
node-negative invasive breast cancer. The total
scores are assigned to a low, moderate or high
category of risk of 10-year recurrence. The
Mammostrat score should then be used as a
guide to inform clinicians on the possible risk
and aid decisions regarding adjuvant treatment.
Mammostrat requires central processing at a
laboratory in the USA [26]. It is not recom-
mended for use by NICE in the UK or by ASCO
[40].
Development of the Tool
Mammostrat was developed in 2006 at the
Comprehensive Cancer Institute of Huntsville,
Alabama, USA [41]. The discovery cohort com-
prised 466 patients with primary invasive breast
cancer presenting to the unit. The age range of
the patients was not disclosed; however, 327
(71%) were aged[50 years and 135
(29%)\ 50 years. Over 140 biomarkers were
stained on the tumour samples, and Cox pro-
portional hazards analysis identified the mini-
mum panel of reagents to be able to predict risk
of recurrence at 5 years.
Validation of the Tool
The test was validated on two cohorts [41]. The
first cohort consisted of 229 patients with pri-
mary invasive breast cancer who presented to
the Cleveland Clinic Foundation between 1995
and 1996. Of the cohort, 225 (75%) of patients
were aged[50 years; the age range of patients
is not provided. Follow-up data was available for
up to 5 years.
The second cohort consisted of 344 patients
who presented to Vancouver General Hospital
between 1974 and 1995 [42]. The age range of
this cohort is also not provided. Follow-up data
was available for up to 11.7 years.
In both these cohorts, Kaplan–Meier esti-
mates of recurrence based on the Mammostrat
model distinguished patients with poor out-
comes following surgery [41].
There is no evidence for using Mammostrat
outside of this setting at the present time.
Validation of the Tool in Older Women
The prognostic power of Mammostrat was fur-
ther validated in a study involving 711 tamox-
ifen-treated patients with ER-positive and node-
negative tumours combined from the NSABP
B-14 and B-20 studies, one of which was the
same trial used to validate Oncotype DX, as
described above. In the B-14 study population,
1804 out of 2615 (69%) patients were[50 years
of age, and in the B-20 clinical study 420 out of
771 patients (55%) were in this age group [43].
The upper age limit of patients included in
these studies is not clear. Analysis of the Mam-
mostrat model was significantly associated with
risk of recurrence in ER-positive, node-negative
tumours, irrespective of the age of the patient.
This study further looked at the benefit of
adjuvant chemotherapy in patients from the
B-20 study population who were already
receiving adjuvant tamoxifen. Specifically, in
patients aged C 60 years, Mammostrat cate-
gorised 22% of patients as high risk of recur-
rence and predicted that there was a 21%
decrease in recurrence rate if these patients
received adjuvant chemotherapy in addition to
tamoxifen. The age stratification was not pre-
specified in the study, and more evidence is
needed to confirm these findings, but these
results suggest that Mammostrat may be useful
for older patients [39]
Bartlett et al. [44] performed Mammostrat in
4598 patients from the Tamoxifen Exemestane
Adjuvant Multinational (TEAM) trial [45], a
multinational randomised trial comparing
exemestane alone or following tamoxifen for
5 years as adjuvant therapy in postmenopausal
patients with early PgR/ER-positive invasive
breast cancer. The TEAM trial included women
with a median age of 64 years (range 34–96).
Mammostrat accurately predicted distant
recurrence-free survival (DRFS) for patients
treated with exemestane and patients treated
with tamoxifen followed by exemestane, irre-
spective of nodal status and chemotherapy. The
ability of this test to provide additional out-
come data after treatment is evidence for its use
in risk stratification of ER-positive tumours in
postmenopausal patients receiving an aro-
matase inhibitor [44].
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Summary
The evidence for use of Mammostrat in older
women is growing. A breakdown of the results
by age from the TEAM trial data would be
helpful.
Prosigna/PAM50
Clinical Utility
The Prosigna assay (based on the PAM50 sig-
nature) measures 58 genes (50 cancer-related
genes and eight controls) and classifies a
patient’s tumour into a subtype based on the
signature (luminal A, luminal B, HER-2 enri-
ched or basal-like) [46]. The test is designed for
postmenopausal women with early, ER-positive,
HER2-negative breast cancer with up to three
positive lymph nodes, receiving 5 years of hor-
monal therapy [14]. The results of the test pro-
vide a risk of recurrence after 10 years (from
diagnosis), in the form of a risk of recurrence
(ROR) score from 1 to 100. A score of 100 indi-
cates the highest risk of recurrence. This score
can further categorise patients into low, inter-
mediate or high risk based on nodal status
[47, 48]. A low risk score indicates\10% pre-
dicted risk of distant recurrence, intermediate
score indicates 10–20% and high risk indicates
more than 20% risk. These scores can be used to
aid the clinician’s decision-making about whe-
ther to use adjuvant chemotherapy in a patient
[49].
Prosigna is recommended by NICE for guid-
ing the use of adjuvant therapy in ER-positive,
HER2-negative, node-negative breast cancer
[26]. The test is also recommended in the same
context by ASCO, in conjunction with other
clinicopathological variables [40]
Development of the Tool
The tool was developed in 2009 using tumour
tissue obtained from multiple centres across the
USA [50]. An expanded gene set of over 1900
genes was measured in 189 breast tumour sam-
ples and profiled by cluster analysis. The mean
age of the sample group was 58 years (standard
deviation 15 years, age range not provided). A
minimised gene set was derived to select the 50
most distinguishing genes, which were
correlated with standard clinical variables and
time to relapse. Test sets from 761 patients who
did not receive any systemic therapy and 133
who received neoadjuvant chemotherapy were
evaluated for concordance [50].
Validation of the Tool
Dowsett et al. [51] compared the PAM50 risk of
recurrence score with that of Oncotype DX.
mRNA was taken from 1017 patients (mean age
64.4 years, standard deviation 8.3 years, age
range not available) with ER-positive early
breast cancer enrolled in the Arimidex,
Tamoxifen, Alone or in Combination (ATAC)
trial [52], and concordance tests were used to
assess the prognostic information provided by
each of the scores. The ATAC trial was a ran-
domised trial to compare anastrozole with
tamoxifen for the adjuvant treatment of early
breast cancer in postmenopausal women [53].
Dowsett et al. [51] showed that PAM50 provided
more prognostic information in endocrine-
treated patients with ER-positive, node-negative
disease than Oncotype DX. Furthermore,
PAM50 could differentiate more clearly between
patients in intermediate- and high-risk groups.
A recent study has looked at the performance
of PAM50 in the neoadjuvant setting using CNB
[54]. The study evaluated the feasibility of using
the assay on CNB samples before assessing the
response to neoadjuvant chemotherapy in HR-
positive, HER2-negative tumour samples. The
study population comprised 95 patients,
resulting in 122 formalin-fixed paraffin-embed-
ded (FFPE) tumour blocks; information about
the patient’s age was not provided. The corre-
lation between paired surgical resection and
CNB samples was high (r [0.90). This study
demonstrated that PAM50 could be measured
accurately in CNB specimens.
Validation of the Tool in Older Women
In 2014, PAM50 was validated on samples from
1478 postmenopausal women with ER-positive
early breast cancer [55]. These samples were
drawn from the archived Austrian Breast and
Colorectal Cancer Study Group (ABCSG) 8
cohort. In this trial, postmenopausal patients
were randomly selected to receive tamoxifen for
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either 5 or 2 years followed by anastrozole for
3 years. The median age of patients was 64 years
(range 41.4–80). None of the patients in this test
set received adjuvant chemotherapy. The study
concluded that the test was suitable for pre-
dicting the risk of recurrence (after 10 years) in
postmenopausal women with ER-positive
tumours. The risk of recurrence at 10 years
was\ 3.5% in the low-risk category, a finding
that could help guide adjuvant chemotherapy.
Summary
PAM50 has been specifically validated in
women up to the age of 80 years and is recom-
mended for use in postmenopausal women.
EndoPredict
Clinical Utility
EndoPredict is a genomic test comprising the
measurement of 12 genes: eight cancer-related
(BIRC5, UBE2C, DHCR7, RBBP8, IL6ST, AZGP1,
MGP, and STC2), three reference genes CALM2,
OAZ1, and RPL37A) and one DNA reference
gene. The test is designed for women with early,
ER-positive, HER2-negative breast cancer with
up to three positive lymph nodes. Measurement
of these genes generates an EPclin score, which
estimates the risk of metastasis within 10 years,
assuming 5 years of adjuvant endocrine ther-
apy. A score of 0–5 indicates low risk (less than
10% risk of metastasis in 10 years) and[5–15
indicates high risk of recurrence [15], which can
be used when considering adjuvant treatment.
Development of the Tool
EndoPredict was developed in Austria in 2011
from samples of 964 ER-positive HER2-negative
tumours in patients treated with surgery fol-
lowed by adjuvant tamoxifen [56]. Patient
samples were collected from two centres. The
median age of this cohort was 65.8 years (range
40.0–93.5). RNA levels of the genes of interest
were assessed by reverse transcriptase poly-
merase chain reaction (PCR) and generated a
score, along with additional clinicopathological
characteristics such as tumour size and nodal
status, to discriminate patients into high or low
risk of recurrence.
NICE and ASCO recommend EndoPredict as
an option when considering adjuvant
chemotherapy in ER-positive, HER2-negative,
node-negative patients [26, 40].
Validation of the Tool
The test was independently validated on two
cohorts of patients enrolled into two ran-
domised trials at the ABCSG, the ABCSG-6 [57]
(n = 378) and ABCSG-8 [58] trials (described
above) (n = 1324) [56].
The ABCSG-6 was a phase III trial in post-
menopausal women comparing adjuvant
tamoxifen alone for 5 years with tamoxifen and
aminoglutethimide for the first 2 years. The
median age of this group was 65.6 years (range
43.7–80.7). In the ABCSG-8 group, post-
menopausal patients were randomly selected to
receive tamoxifen for either 5 or 2 years, fol-
lowed by anastrozole for 3 years. The median
age for this group was 63.4 years (range
41.5–80.5).
The EPclin score was calculated and evalu-
ated using multivariate Cox analysis, and the
risk score was found to be an independent pre-
dictor of distant recurrence in both cohorts.
Mueller et al. [59] specifically compared
EndoPredict performance between CNB and
surgical specimens. The study population com-
prised 40 patients with ER-positive, HER-2 neg-
ative breast cancer. No information about the
patients’ ages is provided. Each patient gave two
samples, one CNB and one surgical resection,
and the samples were compared. The RNA yield
was considerably lower for the CNB but enough
to measure an assay in all samples. The
EndoPredict score was highly correlated (p:
0.92) in the paired samples. These results sug-
gest that EndoPredict could be used in samples
from CNB, but more evidence would need to be
gathered from a larger sample.
EndoPredict has also been evaluated for its
prediction of response to neoadjuvant
chemotherapy [60]. Bertucci et al. analysed data
from 553 ER-positive, HER2-negative tumour
samples treated with neoadjuvant therapy, and
looked at the EPclin prediction of pCR. They
tested EndoPredict on surgical specimens, fol-
lowing neoadjuvant treatment. The overall pCR
rate was 12%. EndoPredict was associated with a
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pCR rate in 7% of the low-risk group and 17% of
the high-risk group. Further evidence is needed
to validate EndoPredict in this setting.
Validation of the Tool in Older Women
Further validation of EndoPredict was per-
formed in a cohort of patients from the phase
III, randomised Group Espan˜ol de Investigacio´n
en Ca´ncer de Mama (GEICAM) 9906 trial look-
ing at postmenopausal women treated with
adjuvant chemotherapy and endocrine therapy
[61]. The patients were randomised to receive
either six cycles of fluorouracil, epirubicin and
cyclophosphamide (FEC) or four cycles of FEC
and then eight weekly courses of paclitaxel
(FEC-P). Those with HR-positive tumours also
received endocrine therapy. The cohort con-
sisted of 555 patients with ER-positive, HER2-
negative, node-positive breast cancer. The study
included 250 (45%) patients aged\50 years
and 305 (55%) aged C 50 years. The study
showed EndoPredict to be an independent
prognostic marker of recurrence at 10 years.
Summary
There is evidence to support the use of
EndoPredict in older women up to the age of
80 years. Subgroup analysis by age in the
ABCSG trials would be helpful to determine the
exact number of older women included.
IHC4
Clinical Utility
Immunohistochemical 4 (IHC4) is a model
incorporating four immunohistochemical
markers: ER, PgR, HER2 and ki67. The model is
designed for use in early breast cancer patients
receiving surgery followed by 5 years of adju-
vant endocrine therapy, and predicts the risk of
distant recurrence after 10 years [46].
Following on from IHC4, the IHC4?C prog-
nostic tool has been developed [62]. The
IHC4?C score incorporates the four markers
along with the clinicopathological (?C) factors
of nodal burden, tumour grade and size, patient
age, and treatment with AI or tamoxifen [63]
The tool calculates a risk of recurrence score,
with low risk indicating less than 10% chance of
distant recurrence within 10 years, intermediate
risk 10–20%, and high risk[20%. This score
can be used by clinicians to aid in decisions
about whether a patient can forgo adjuvant
therapy.
In the most recent NICE guidance, IHC4?C
was not recommended to be used when con-
sidering adjuvant chemotherapy decisions, due
to uncertain analytical validity of the test [52].
This decision was bolstered by the fact that
patients in the trials had not undergone adju-
vant chemotherapy [62]. In the UK, the
IHC4?C test is currently performed only at the
Royal Marsden Hospital; the average turn-
around time for the test is 1 week.
ASCO does not recommend the use of IHC4
[40]
Development of the Tool
The tool was developed in 2011 at the Wolfson
Institute of Preventative Medicine, London, UK.
The four markers were measured on patients
included in the translational arm of the ATAC
cohort [62], as previously described. For the
purposes of testing IHC4, 1225 patients with
ER-positive breast cancer, and sufficient good-
quality tissue for IHC testing were selected from
the ATAC cohort. The median age of the cohort
selected was 64 years (range 57–70). A prog-
nostic model to estimate recurrence was devel-
oped based on the measurement of the four
markers in this cohort.
Validation of the Tool
The tool was first compared with the Oncotype
DX Recurrence Score, which was also tested on
the ATAC cohort. IHC4 was found to provide
similar prognostic information [64].
The model was initially validated in a cohort
of 786 patients treated in Nottingham between
1990 and 1998 [63, 65]. The Nottingham cohort
had a median age of 55 years (range 48–63) and
was not restricted by menopausal status. All
patients had ER-positive tumours and received
either tamoxifen or no treatment as adjuvant
therapy. The IHC4 score was highly signifi-
cantly prognostic for outcome in this cohort.
The IHC4?C score was developed in retro-
spective analysis of the ATAC cohort, once the
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independent prognostic power of IHC4 had
been established in endocrine patients [53].
The IHC4 tool was then further validated in
the TEAM trial [64]. IHC4 was quantified on
2919 of the TEAM samples (as previously
described). The breakdown by age is not pub-
lished for this subset, nor are the criteria for
selection. The results showed the IHC4 algo-
rithm to be effective in predicting residual risk
following endocrine therapy in postmenopausal
patients.
A recent study showed the potential to use
IHC4 on core needle biopsy (CNB) specimens,
as an alternative to surgical excision (SE) sec-
tions [64]. Core biopsy samples from 108
patients diagnosed with invasive breast cancer
were retrieved. None of the patients had been
treated with neoadjuvant therapy. The mean
age of participants in the study was 49 years
(range 29–82). Paired CNB and SE samples were
evaluated for IHC4 scores, and the two were
analysed for concordance.
The results of the study showed that CNB
had moderate concordance with SE scores and
therefore could be used for IHC4 testing, pro-
vided an adequate amount of CNB tissue was
available. This is an exciting possibility, which
would allow use of IHC4 in the neoadjuvant
and primary settings. One potential drawback as
noted by this study was that the total length of
malignant tissue obtained was inversely pro-
portional to age, and increased atrophy was
seen in older patients; therefore, greater care
would be needed in obtaining a sample in this
manner. The study noted that in general, low
concordance was related to a low number of
cores obtained; however, the number of cores
did not differ between younger and older
patients. It was specifically tumour tissue atro-
phy that seemed to contribute to this factor.
This suggests a possible disadvantage for older
women if CNB were to become the mainstay for
obtaining tumour samples for profiling.
Validation of the Tool in Older Women
Although initially designed based on a cohort of
younger women, validation of IHC4 using
TEAM trial data has included some older
women, although the exact number is unclear.
Based on this, further validation of IHC4 is
needed to determine its value in older women.
Furthermore, IHC4 is based on the prediction of
recurrence following adjuvant therapy and is
only validated in this setting.
Summary
The analytical validity for IHC4 is currently
scant and there is very little evidence for its use
in older women, although the findings relating
to tissue quality in older women from the CNB
study present an interesting concept [64].
CONCLUSIONS AND FUTURE
DIRECTIONS
Summary of Existing Tools
Oncotype DX stands out as the only tool vali-
dated for both predictive and prognostic utility.
It is the most used tool in the USA and has the
largest body of evidence in terms of trials con-
ducted and research undertaken [13, 66]. The
large-scale TAILORx study [36] was promising in
its recruitment of older women, but in the
intermediate-risk group the study focused on,
only 4.3% of the women were over 70 years old.
RxPONDER [41] may shed further light, as there
is no age limit, but the results remain to be seen.
As the oldest tool, MammaPrint also has boun-
tiful evidence and scope for use as both a pre-
dictive and prognostic tool. However, in the
ongoing MINDACT trial [23, 27], only 1% of the
recruits are over 70 years. It was also validated
on younger women of\ 53 years [18].
Many of the key trials concerning Mam-
mostrat only provide age information of cate-
gories of\ 50 or[50 years. There is overall less
evidence for Mammostrat. The TEAM trial [45]
(also concerning IHC4) includes patients up to
the age of 96, but further breakdown by age has
not been provided, which makes the results
difficult to analyse in this way.
PAM50 is specifically recommended for
postmenopausal women only, which implies it
may be preferential to an older group. In addi-
tion, unlike the other tests, its classification by
subtype may pose an advantage in terms of
tumour heterogeneity by age. However, since its
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validation there has been no contribution to
the evidence for its use in older women.
EndoPredict has evidence to support its use
in patients up to the age of 80 years, but like
PAM50 has not been included in trials con-
cerning older women since its inception. The
GEICAM 9906 trial [61] includes 55% who are
over 50 years of age, but further breakdown is
not provided.
The newest tool, IHC4, is also included in
the TEAM trial, but as previously mentioned,
information about age is lacking.
Current Issues with the Use of Tumour
Profiling Tools in Older Women
Age Range
From this review, it is clear that overall there is a
lack of evidence specific to older women, which
is echoed in clinical trials of new therapies and
research in general. This is partly due to lack of
recruitment of older women, and where older
women are recruited, numbers are few. This
may be due to failure of inclusion by the
researchers or lack of willingness to participate
by the patient due to competing comorbidities
or concern of the impact on treatment or
quality of life.
Where older women are included, often
analysis by age is not done, or a breakdown of
results by age not given. This makes it difficult
to interpret the results in this specific cohort.
Setting
Current tools available are focused mainly on
ER-positive tumours and considering adjuvant
treatment decision-making, especially
chemotherapy. Although the majority of breast
cancers in older women are ER-positive, there is
an important group of patients who are ER-
negative. Especially if the patient is unfit for or
declines surgery, we need to know what alter-
native treatments are available to them, as PET
is not recommended.
Sample Required
The tumour profiling tools were initially devel-
oped and validated on surgical excisions. More
recent studies have enabled testing on CNB
specimens [67]
The use of core needle biopsy presents a
degree of uncertainty, and some studies have
shown discordance between different markers,
particularly PgR when it comes to CNB [31, 32].
As of 2016, Oncotype DX had been performed
600,000 times and in CNB 20% of the time [32].
The evidence is unclear, and although all of the
tools (except Mammostrat) have been tested in
CNB samples, most studies of this kind involve
small sample sizes. This is an important area for
future research.
VAB is also an emerging tool, although the
evidence for its use in combination with the
genomic tools is scant; only MammaPrint [22]
had been tested in a small population for fea-
sibility in this source.
Cost Effectiveness
As the only validated predictive tool, Oncotype
DX is used worldwide, and its cost effectiveness
has been considered widely. NICE’s estimated
cost for the test was £2850 [26], the most
expensive of all the tools considered here. The
possibility has been raised of reducing costs by
using traditional pathological tests as a way of
screening for Oncotype DX requirement. This is
currently recommended by NICE with the use
of PREDICT or NPI. Gage et al. [68] analysed
information about 1268 breast cancer patients
from the University of Texas MD Anderson
Cancer Center database. The mean age of the
group was 54.8 years. The aim of the study was
to conclude whether using a pathologic-ge-
nomic algorithm could avoid the use of Onco-
type DX in low- and high-risk categories. The
team compared the Oncotype DX RS scores
with the Anne Arundel Medical Center (AAMC)
model predictions, which use standard pathol-
ogy data. Five-year distant recurrence rates were
shown to be similar in the AAMC low-risk group
(2.7%, n = 322) and the RS low-risk (\ 18 RS)
group (3.4%, n = 703). The high-risk group was
also well correlated: AAMC (22.8%, n = 230)
and the Oncotype DX RS[30 (23.0%, n = 141).
The algorithm predicted that risk of metastasis
was 3.3% for the low-risk group (n = 739) and
24.2% for the high-risk group (n = 272). In
theory, by using this algorithm and reserving
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genomic testing for the intermediate-risk group,
44% of the patients (n = 522) could have avoi-
ded the Oncotype DX testing.
Tumour profiling tests are expensive to
conduct. NICE’s Economic Analysis Group
estimated the costs to be as follows: Mam-
maPrint (£2326), Oncotype DX (£2580), Mam-
mostrat (£1135), EndoPredict (£1500), Prosigna
(£1970) and IHC4 (£203) [26]. In light of this,
NICE recommends reserving the tools for
patients in an intermediate-risk category as
predicted by a traditional non-genomic tool.
Perhaps a more relevant consideration for older
patients is cost analysis in terms of quality-ad-
justed life-years.
Limitations of the Current Study
Many of the salient studies did not share
information about results by age, or specifics
about numbers of participants in older age cat-
egories. This means that interpretation of these
studies has been somewhat limited. Due to
variations in healthcare systems and regulatory
bodies worldwide, the use of the tools in dif-
ferent countries can be difficult to interpret.
Future Directions
In summary, the evidence for use of the tools
discussed in this article specific to older women
with primary breast cancer is lacking. These
tools are most often derived from and validated
in cohorts of patients consisting entirely of
younger women, or including a small number
of older women. The tools are mainly focused
on predicting the benefit of adjuvant therapy
after surgery, and therefore cannot provide any
useful information in the cohort of older
women who have PET.
If it were possible to provide a breakdown by
age of the current available studies, this would
greatly add to the evidence base for use of these
tools in older women.
There needs to be greater recognition and
focus specifically on the older population when
it comes to validating existing tools and in the
development of new tumour-based tools. A lack
of information means that categories such as
postmenopausal and age[50 years are falsely
attributed to the evidence base for older
women. The biology of breast cancer in older
women has been shown to have different bio-
logical features compared to their younger
counterparts; in the era of personalised treat-
ments, their unique tumour biology can no
longer be ignored.
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